A Phase 3 interventional study of Ertugliflozin 5 mg and Ertugliflozin 15 mg in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-12-07.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 — 3 open to participants now, 3 under way, none of them phase 3. ertugliflozin · Diabetes Mellitus, Type 2.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, this one is the 5th largest by enrollment, is the only one that started in 2015, is one of 11 in phase 3, and was the 17th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →3 of the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:
Amsterdam UMC, location VUmc · Sites in United States, Netherlands
Ages 18–85
Baylor Research Institute · Sites in United States
Ages 18–84
Shanghai Zhongshan Hospital · Sites in China
Ages 19+
By country, each count listing its studies:
ertugliflozin: first FDA approval 2017 (STEGLATRO), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 506 is above the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 83 across the 28 interventional studies. Of the 24 that completed or were terminated, 19 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 28 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 181 finished, 150 (83%) have results posted.
Among the 181 studies in Diabetes Mellitus, Type 2 by Merck & Co., Inc, this one is the 44th largest by enrollment of the 170 interventional ones that give a count, is one of 7 that started in 2015, is one of 86 in phase 3, and was the 173rd registered.
Merck & Co., Inc’s Diabetes Mellitus, Type 2 studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing ertugliflozin in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 181 in Diabetes Mellitus, Type 2:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the efficacy and safety of the addition of ertugliflozin to metformin monotherapy in Asian participants with Type 2 diabetes mellitis (T2DM) who have inadequate glycemic control on metformin monotherapy. The primary hypothesis is that the mean reduction from baseline in HbA1C for 15 mg and 5 mg ertugliflozin (tested sequentially) is greater than for placebo.
This study includes a 1-week screening period, an 8-week (or greater) antihyperglycemic agent (AHA) wash-off and/or metformin dose stable period (as necessary), a 2-week single-blind placebo run-in period, a 26-week double-blind treatment period, and a post-treatment telephone contact 14 days after the last dose of study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertugliflozin 5 mg oral and matching placebo for ertugliflozin 10 mg, oral, once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
Drug: Ertugliflozin 5 mg · Drug: Placebo matching ertugliflozin · Drug: Metformin · Drug: Glimepiride
Ertugliflozin 15 mg (ertugliflozin 5 mg + ertugliflozin 10 mg) administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
Drug: Ertugliflozin 15 mg · Drug: Metformin · Drug: Glimepiride
Placebo matching ertugliflozin administered orally once daily for 26 weeks, while maintaining metformin at a stable dose (\>=1500 mg/day). Glycemic rescue therapy with open-label glimepiride was initiated in participants with glucose values exceeding protocol-specified values.
Drug: Placebo matching ertugliflozin · Drug: Metformin · Drug: Glimepiride
Ertugliflozin 5 mg oral tablet taken once daily
Also known as: MK-8835, PF-04971729
Ertugliflozin 15 mg (5-mg and 10-mg tablets) oral taken once daily
Also known as: MK-8835, PF-04971729
Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
Participants are to remain on their stable doses of metformin (oral, \>=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin \<1500 at screening are up-titrated to \>= 1500 daily.
Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 28 weeks
Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 28 weeks
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 26 weeks
Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation)
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
Time frame: Up to 26 weeks
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation)
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)
The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation)
The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 26
Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 26
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)
This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)
This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)
This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation)
This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Baseline and Week 26
Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 26
Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation)
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
Time frame: Week 26
Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26.
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.
Time frame: Week 26
Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation)
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.
Time frame: Week 26
Time to Glycemic Rescue Therapy
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.
Time frame: Up to 183 days
Time to Glycemic Rescue Therapy (China Subpopulation)
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.
Time frame: Up to 149 days
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 6: Pre-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 12: Pre-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 12: 60 min. Post-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 18: Pre-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 18: 60 min. Post-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 26: Pre-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 6: Pre-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 12: Pre-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 12: 60 min. Post-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 18: Pre-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 18: 60 min. Post-Dose
Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation)
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
Time frame: Week 26: Pre-Dose
In total, 1078 participants were screened, and 506 participants were randomized at 50 sites in China, Hong Kong, Republic of Korea, the Philippines, and Taiwan.
| Milestone | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Started | 170 | 169 | 167 |
| Treated | 170 | 169 | 167 |
| Completed | 163 | 160 | 157 |
| Not completed | 7 | 9 | 10 |
| Withdrew: Adverse event | 2 | 1 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 2 |
| Withdrew: Physician decision | 1 | 1 | 0 |
| Withdrew: Pregnancy | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 4 | 5 | 7 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage A1C | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) | -1.00 (-1.12 to -0.88) | -0.89 (-1.01 to -0.77) | -0.20 (-0.33 to -0.08) |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage A1C | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in A1C (%) at Week 26 (Excluding Rescue Approach) (China Subpopulation) | -1.01 (-1.14 to -0.87) | -0.92 (-1.05 to -0.79) | -0.24 (-0.38 to -0.10) |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) | 56.5 | 53.3 | 59.3 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach) (China Subpopulation) | 54.4 | 50.4 | 59.3 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) | 1.2 | 0.6 | 1.8 |
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Percentage of Participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach) (China Subpopulation) | 0.7 | 0.7 | 2.2 |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mg/dL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) | -37.09 (-41.73 to -32.45) | -34.47 (-39.15 to -29.79) | -6.69 (-11.57 to -1.82) |
Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mg/dL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach) (China Subpopulation) | -39.01 (-43.87 to -34.15) | -36.67 (-41.64 to -31.71) | -10.46 (-15.61 to -5.31) |
The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Kilograms | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) | -2.95 (-3.29 to -2.60) | -3.18 (-3.52 to -2.83) | -1.17 (-1.54 to -0.81) |
The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Kilograms | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach) (China Subpopulation) | -3.11 (-3.50 to -2.72) | -3.38 (-3.78 to -2.98) | -1.33 (-1.75 to -0.91) |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) | 38.2 | 40.8 | 16.2 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With HbA1c of <7.0% (53 mmol/Mol) (Logistic Regression Using Multiple Imputation Based on cLDA Model: Excluding Rescue Approach) (China Subpopulation) | 35.3 | 42.2 | 18.5 |
This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) | -5.09 (-6.78 to -3.40) | -3.87 (-5.58 to -2.16) | 0.22 (-1.58 to 2.01) |
This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation) | -5.64 (-7.53 to -3.75) | -4.19 (-6.14 to -2.25) | -1.56 (-3.61 to 0.49) |
This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) | -2.38 (-3.51 to -1.25) | -2.36 (-3.50 to -1.22) | -0.96 (-2.16 to 0.24) |
This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| mmHg | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach) (China Subpopulation) | -2.82 (-4.11 to -1.54) | -2.77 (-4.09 to -1.45) | -1.82 (-3.21 to -0.43) |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) | 14.7 | 15.4 | 2.4 |
A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.
| Percentage of participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants With HbA1c of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach) (China Subpopulation) | 14.7 | 17.0 | 3.0 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.
| Percentage of Participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26. | 1.2 | 0.6 | 9.6 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.
| Percentage of Participants | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Percentage of Participants Requiring Glycemic Rescue Therapy Through Week 26 (China Subpopulation) | 0.0 | 0.7 | 9.6 |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.
| Days | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Time to Glycemic Rescue Therapy | NA (41 to 85) | NA (149 to 149) | NA (22 to 183) |
Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride and dosed according to Investigator judgment.
| Days | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Time to Glycemic Rescue Therapy (China Subpopulation) | — | NA (149 to 149) | NA (22 to 145) |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach | 9.17 ± 18.39 | 24.59 ± 43.84 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach | 8.18 ± 15.25 | 27.11 ± 66.02 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach | 91.49 ± 50.61 | 277.60 ± 130.66 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach | 6.59 ± 12.53 | 17.54 ± 24.62 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach | 91.40 ± 44.77 | 274.23 ± 146.14 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach | 7.34 ± 14.18 | 26.66 ± 62.17 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation) | 7.88 ± 14.88 | 22.29 ± 42.81 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation) | 7.40 ± 12.21 | 23.84 ± 52.64 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation) | 97.36 ± 48.98 | 294.49 ± 124.73 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation) | 6.30 ± 11.50 | 17.07 ± 27.06 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation) | 94.82 ± 41.40 | 285.28 ± 141.59 | — |
No ertugliflozin plasma concentrations were determined for participants receiving placebo. Lower limit of quantification for ertugliflozin was 0.500 ng/mL.
| ng/mL | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Ertugliflozin Plasma Concentrations Summary Statistics Over Time: Including Rescue Approach (China Subpopulation) | 7.26 ± 14.09 | 24.91 ± 57.95 | — |
Collected over Up to 28 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertugliflozin 5 mg | 0/170 (0%) | 9/170 (5.3%) | 22/170 (12.9%) |
| Ertugliflozin 15 mg | 0/169 (0%) | 10/169 (5.9%) | 31/169 (18.3%) |
| Placebo | 0/167 (0%) | 2/167 (1.2%) | 44/167 (26.3%) |
| Event | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| Diabetes mellitus inadequate controlMetabolism and nutrition disorders | 0/170 | 0/169 | 1/167 |
| Cubital tunnel syndromeNervous system disorders | 0/170 | 0/169 | 1/167 |
| Microvascular coronary artery diseaseCardiac disorders | 0/170 | 1/169 | 0/167 |
| Vertigo positionalEar and labyrinth disorders | 0/170 | 1/169 | 0/167 |
| Dacryostenosis acquiredEye disorders | 0/170 | 1/169 | 0/167 |
| PneumoniaInfections and infestations | 0/170 | 1/169 | 0/167 |
| Blood glucose increasedInvestigations | 0/170 | 1/169 | 0/167 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 1/170 | 1/169 | 0/167 |
| Clear cell renal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/170 | 1/169 | 0/167 |
| Rectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/170 | 1/169 | 0/167 |
| Event | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo |
|---|---|---|---|
| HyperuricaemiaMetabolism and nutrition disorders | 5/170 | 9/169 | 20/167 |
| Upper respiratory tract infectionInfections and infestations | 4/170 | 9/169 | 14/167 |
| NasopharyngitisInfections and infestations | 9/170 | 9/169 | 11/167 |
| HypoglycaemiaMetabolism and nutrition disorders | 6/170 | 9/169 | 2/167 |
The analysis population included all randomized participants who received at least one dose of investigational product.
| Age, Continuous(Years) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 56.1 ± 9.0 | 56.3 ± 9.3 | 56.9 ± 9.0 | 56.5 ± 9.1 |
| Sex: Female, Male(Participants) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Female | 75 | 71 | 79 | 225 |
| Male | 95 | 98 | 88 | 281 |
| Race (NIH/OMB)(Participants) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 170 | 169 | 167 | 506 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Body Weight(Kilograms) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 71.4 ± 11.1 | 69.5 ± 10.9 | 70.1 ± 12.4 | 70.3 ± 11.5 |
| Baseline Hemoglobin A1C (A1C)(Percentage A1C) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 8.14 ± 0.89 | 8.09 ± 0.91 | 8.13 ± 0.96 | 8.12 ± 0.92 |
| Baseline Fasting Plasma Glucose (FPG)(mg/dL) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 170.1 ± 36.0 | 167.3 ± 41.1 | 165.8 ± 37.6 | 167.8 ± 38.3 |
| Baseline estimated glomerular filtration rate (eGFR)(mL/min/1.73 m^2) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| Mean | 97.9 ± 19.2 | 100.2 ± 19.8 | 99.9 ± 20.2 | 99.3 ± 19.7 |
| Country(Participants) | Ertugliflozin 5 mg | Ertugliflozin 15 mg | Placebo | Total |
|---|---|---|---|---|
| China | 136 | 135 | 135 | 406 |
| Hong Kong | 10 | 10 | 7 | 27 |
| Korea, Republic of | 13 | 10 | 9 | 32 |
| Philippines | 7 | 8 | 8 | 23 |
| Taiwan | 4 | 6 | 8 | 18 |
8 further baseline measures are reported on the registry.
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf
Data sharing details ↗ · engagezone.msd.com
Ran from Dec 2015 to primary completion in Dec 2017, 24 months.
Results were first posted in Dec 2018, 11 months after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 24 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertugliflozin